361 related articles for article (PubMed ID: 31131591)
1. Oral and intravenous fosfomycin in complicated urinary tract infections.
López-Montesinos I; Horcajada JP
Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
[TBL] [Abstract][Full Text] [Related]
2. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
[TBL] [Abstract][Full Text] [Related]
3. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.
Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG
Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723
[TBL] [Abstract][Full Text] [Related]
4. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.
Burgos RM; Rodvold KA
Future Microbiol; 2019 Apr; 14():461-475. PubMed ID: 30854892
[TBL] [Abstract][Full Text] [Related]
5. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
Reffert JL; Smith WJ
Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
[TBL] [Abstract][Full Text] [Related]
6. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.
Matthews PC; Barrett LK; Warren S; Stoesser N; Snelling M; Scarborough M; Jones N
BMC Infect Dis; 2016 Oct; 16(1):556. PubMed ID: 27729016
[TBL] [Abstract][Full Text] [Related]
7. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
Shorr AF; Pogue JM; Mohr JF
Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
[TBL] [Abstract][Full Text] [Related]
8. The revival of fosfomycin.
Michalopoulos AS; Livaditis IG; Gougoutas V
Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
[TBL] [Abstract][Full Text] [Related]
9. [Fosfomycin: past, present and future].
Baylan O
Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
[TBL] [Abstract][Full Text] [Related]
10. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
11. [The role of fosfomycin in the management of urinary tract infections].
Zaitsev AV; Kolontarev KB
Urologiia; 2017 Sep; (4):91-96. PubMed ID: 28952700
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
[TBL] [Abstract][Full Text] [Related]
14. "Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla
Rosa R; Rudin SD; Rojas LJ; Hujer AM; Perez-Cardona A; Perez F; Bonomo RA; Martinez O; Abbo LM; Camargo JF
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29064133
[TBL] [Abstract][Full Text] [Related]
15. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
[TBL] [Abstract][Full Text] [Related]
16. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers.
Wijma RA; Koch BCP; van Gelder T; Mouton JW
Clin Microbiol Infect; 2018 May; 24(5):528-532. PubMed ID: 28867662
[TBL] [Abstract][Full Text] [Related]
17. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
[TBL] [Abstract][Full Text] [Related]
18. Fosfomycin: an old--new antibiotic.
Raz R
Clin Microbiol Infect; 2012 Jan; 18(1):4-7. PubMed ID: 21914036
[TBL] [Abstract][Full Text] [Related]
19. [Fosfomycin trometamol: multiple-dose regimen for the treatment of lower urinary tract infections].
Sádaba-Díaz de Rada B; Azanza-Perea JR; García-Quetglas E; Honorato-Pérez J
Enferm Infecc Microbiol Clin; 2006 Nov; 24(9):546-50. PubMed ID: 17125672
[TBL] [Abstract][Full Text] [Related]
20. Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-Results of a Spanish multicenter cohort.
López-Medrano F; Silva JT; Fernández-Ruiz M; Vidal E; Origüen J; Calvo-Cano A; Luna-Huerta E; Merino E; Hernández D; Jironda-Gallegos C; Escudero R; Gioia F; Moreno A; Roca C; Cordero E; Janeiro D; Sánchez-Sobrino B; Montero MM; Redondo D; Candel FJ; Pérez-Flores I; Armiñanzas C; González-Rico C; Fariñas MC; Rodrigo E; Loeches B; López-Oliva MO; Montejo M; Lauzurica R; Horcajada JP; Pascual J; Andrés A; Aguado JM;
Am J Transplant; 2020 Feb; 20(2):451-462. PubMed ID: 31550408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
